The present invention relates generally to the field of in vivo detection and/or quantification of analytes. More specifically, the present invention relates to systems and methods for detecting, analyzing, and/or quantifying concentrations of compounds by measuring the spectral responses of sensitized particles embedded within tissue such as the skin.
Raman spectroscopy is a powerful tool for revealing specific molecular signatures from a complex system. For glucose in vivo detection, a Raman excitation laser emitting in the near IR region of the spectrum can penetrate into tissues to probe the molecular vibration which can not be done by IR spectroscopy due to strong water absorption. However, Raman scattering is a nonlinear process and tends to have a very small cross section (i.e., approximately 10−30 cm−2 sr−1 molecule−1). Two known approaches for enhancing Raman scattering processes are surface enhanced Raman spectroscopy (SERS) and UV resonance enhanced Raman. UV resonance enhanced Raman is less appropriate for in vivo detection applications because of limitations in the tissue transparency window. Specifically, UV radiation is strongly absorbed by human tissue, and glucose does not undergo electronic resonance in the visible or near-infrared regions of the spectrum. SERS analysis of glucose using silver nano-particles may enhance Raman scattering by more than million times.
The historic difficulty of SERS detection of glucose in vivo using prior art methods may be attributable to the weak or nonexistent binding of glucose to bare silver surfaces. The normal Raman cross section of glucose should provide a sufficient signal for detection and quantification. Experiments performed by Weaver and co-workers (Mrozek, M. F.; Weaver, M. J. Anal. Chem. 2002, 74, 4069-4075) indicate that glucose must be trapped in a junction between the roughened electrode and the colloidal nano-particles. The stability of SERS activity has been unambiguously demonstrated for bare silver films over nano-sphere (AgFON) surfaces over a potential range from Ag oxidation to H2 evolution and at high temperatures in ultrahigh vacuum, as reported in Dick, L. A.; McFarland, A. D.; Haynes, C. L.; Van Duyne, R. P. J. Phys. Chem. B 2002, 106, 853-860, and Litorja, M.; Haynes, C. L.; Haes, A. J.; Jensen, T. R.; Van Duyne, R. P. J. Phys. Chem. B 2001, 105, 6907-6915.
Because of the advantages of SERS detection techniques for glucose, a system and method for applying this detection technique in vivo is desirable. The present invention provides a novel approach to the problem, using SERS-active nano-particles that are implanted in a subject in a manner similar to tattooing.
The present invention provides for in vivo optical detection of analytes (e.g., glucose) by embedding small particles within the dermis of the skin. The small particles are made sensitive to the analyte of interest by construction. For example, silver-coated nanoparticles further covered with a self-assembled molecular monolayer are suitably sensitized for the detection of glucose. The particles embedded within the dermis are preferably probed by surface enhanced Raman spectroscopy, although other optical probe techniques can be employed.
A first embodiment of the present invention provides a method for in vivo detection of an analyte in a subject. Sensitized particles having an adsorptive affinity for the analyte are embedded within the skin of the subject. The analyte concentration at the surface of the sensitized particles is greater than the analyte concentration in the subject. The sensitized particles are optically illuminated with excitation radiation. Optical radiation emitted by the sensitized particles is collected and measured. The emitted radiation is analyzed to detect the analyte and/or quantify the concentration of the analyte in the subject.
In an alternative embodiment, an apparatus is provided for in vivo determination of an analyte. The apparatus comprises a housing that is attachable to a subject's arm by a strap such that a face of the housing is approximately flush with a skin surface on the subject's arm. The housing contains an optical path for conveying an incident beam of excitation light from an excitation source and for conveying collected scattered radiation to a detector. This optical path comprises an angled mirror to direct the incident beam approximately perpendicular to the skin and a focusing lens that focuses the incident beam on a tattoo spot in the skin and focuses the scattered radiation emitted from the tattoo spot
Other objects and advantages of the present invention will become apparent upon reading the detailed description of the invention and the appended claims provided below, and upon reference to the drawings, in which:
a is a schematic diagram showing placement of a monitoring device according to the present invention designed to be worn on the wrist.
FIG.2 is a schematic diagram showing silver nano particles made by coating silver over uniform polystyrene latex nano-spheres that are further covered with a self-assembled molecular monolayer.
FIG.3 is a schematic diagram showing a view of human skin structure and physiology.
FIG.4 is a schematic diagram showing the distribution of tattoo ink particles at various stages of a tattoo implanting process for use with one or more of the embodiments of the present invention.
FIG.5 is a schematic diagram showing a side view of an embodiment of the invention in which excitation light from a laser source passes through a collimating lens, beam splitter, right angle mirror and a focusing lens onto a tattoo spot.
FIG.6 is a chart showing calculated contour lines of absorbed energy based on a skin model, for the case of a narrow incident beam (the 1/e2 radius of the incident beam is approxaimtely 0.01 cm).
FIG.7 is a schematic diagram showing a modification of the embodiment shown in
FIG.8 is a schematic diagram showing a top view (i.e., looking down on the skin) of the apparatus shown in
FIG.9 is a chart showing Raman spectra of various compositions.
FIG.10 is a schematic diagram showing a modification of the embodiment of
FIG.11 is a chart showing Raman spectra of various components of the skin, along with a SERS glucose spectrum for comparison.
1. Selective Enhanced Glucose Detection
Detection of glucose (or other analytes) using SERS presents two potential problems. Silver nano-particles (or other sensitized small particles) must be implanted in the human body to effectively make contact with glucose, and the nano-particles must be sensitized to glucose, which generally does not readily adhere to silver surfaces. The present invention solves the first problem by applying well-known tattooing techniques for implantation of sensitized particles.
Referring to
According to one embodiment of the present invention, nano-particles may be implanted within the dermis of the skin as tattoo ink for selective glucose detection via SERS. A round tattoo spot may be made on the inner arm where the skin is thin and lightly colored. The spot is advantageously of approximately 1 mm diameter. The glucose Raman reader may advantageously be configured as a watch on the lower arm (i.e., near wrist as shown on
The second issue with in vivo SERS quantification of glucose involves sensitization of the implanted nano-particles. To increase glucose interaction with a “silver film over nanosphere” (AgFON) surface, a self-assembled monolayer (SAM), as taught by Shafer-Peltier et al, (J. Am. Chem. Soc. 2003, 125 588-593), the disclosure of which is incorporated herein by reference in its entirety, may be formed on an AgFON surface to preconcentrate the analyte of interest. An example of this process is shown schematically in
Surfactant-free white carboxyl-substituted polystyrene latex nanospheres with diameters of 400 nm were coated with silver metal films in the aforementioned Shane-Peltier study. The mass thickness of Ag in all cases was approximately 200 nm. Fresh AgFON samples were incubated in approximately 1 mM solutions of the partition layer self assembled monolayers (SAMs) in ethanol for greater than approximately 12 h for complete coverage. The authors report the growth of a layer of “hair-like” molecular chains on the silver nano particle surface to make up a self-assembled monolayer (SAM). The length of the SAM chains is about 4 nm, comparable to the spatial extent of the surface plasmons, which are exploited in surface enhanced Raman spectroscopy. Various SAM layers were tried, but only straight chain alkanethiols were found to be effective in enhancing the sensitivity to glucose. The SAM selectively adsorbs glucose within its hair-like structure leading to pre-concentration, namely the concentration of glucose in the SAM layer is substantially greater than that in bulk solution. This pre-concentration effect is approximately linearly proportional to the concentration of glucose in the solution. Kinetic analysis also shows a relatively fast (approximately 10 msec) process to reach equilibrium. Therefore, a SAM layer selectively enhances the glucose Raman signal. The self-assembled monolayers (SAMs) used in this work are known to be extremely stable by themselves and as adsorbates on AgFON surfaces. While glucose analysis is described in the instant application to illustrate both the operation and potential advantages of the present invention, other analytes may be detected and quantified in vivo based on the teachings provided herein. One of skill in the art would be able to select and appropriate SAM/sensitized nano-particle system for use with additional analytes using routine experimentation.
A possible kinetic scheme for a SERS-based glucose sensor according to the present invention is
In general, glucose must diffuse from bulk solution, Gbulk, to the solution/alkanethiol SAM interface, S, where it is adsorbed, Gads, and then partitioned, Gpart, into the SAM. IN equation 1, kads is the bimolecular rate constant for adsorption of glucose at the solution/SAM interface, kdes is the unimolecular rate constant for desorption of glucose from the solution/SAM interface, kp is the rate constant for partitioning of glucose into the SAM, and k−p is the rate constant for departitioning of glucose from the SAM. Assuming that the diffusion step is rate limiting, a glucose detector according to the present invention may have a response time of approximately 10 millisecond time.
2. Human Skin Tissue Composition, Structure and Optical Properties
The structure and properties of skin vary considerably in different parts of the body. A typical structure is shown schematically in
The papillary dermis is an advantageous location for glucose detection because it contains the vascular network. The papillary dermis is also the layer in which tattoo ink particles tend to remain, making tattooing a suitable method for implanting sensitized small particles into the human body. By implanting nano-silver particles as tattoo ink, the particles will have sufficient contact with fresh human fluid containing a representative concentration of glucose. As a result, tattoo ink of nano-silver particles will exchange glucose concentration with extracellular fluid, which is next to the capillary vascular network.
3. “Tattoo” Injection of SERS-Enhanced Detection Particles
Tattoo formation. Tattoos are an ancient art form with origins that trace back as far as the Stone Age (12,000 BC). Tattoos have remained popular throughout time and across many cultures and continents. FIG.4 schematically illustrates a generic tattoo forming process. This description, representative of tattooing procedures in general, is published at www.bmezine.com/news/edit/A30205/arttatto.html. Tattoo particles are initially scattered around the pinch wound and are eventually grouped under the epidermis within the upper dermis (papillary layer). When ink is first deposited, as shown in panel (A) of
Tattoo ink. Tattoo ink is remarkably non-reactive histologically, despite widespread use by tattoo artists of a variety of pigments of unknown purity and identity. The most used tattoo inks are nano-particles of inorganic compounds, such as minerals. Tattoo pigment granules are typically composed of particles ranging from approximately 2 to 400 nm in diameter. The most common particle size is approximately 40 nm, less common are approximately 2 to 4 nm particles (slightly more electron dense), and least common are 400-nm particles, which are very electron dense with a crystalline structure. A study of freshly implanted eyeliner tattoo ink revealed particles in the extracellular matrix with diameters of approximately 0.1 to 1.0 μm, although the average particle size in the pigment vial prior to implantation was approximately 0.25 μm.
Silver nano-particles may be prepared with sizes very similar to those of commonly used tattoo ink particles. Chemically, silver nano-particles, advantageously coated with a suitable SMA layer, may be made non-reactive in human tissue like other tattoo inks. Therefore, physically, these particles may perform like tattoo ink particles in the dermis.
FDA regulation. The United States Food and Drug Administration does not currently regulate tattoo procedures and tattoo inks. However, some precautions and guidelines have been published, for example at http://vm.cfsan.fda.gov/-dms/cos-204.html.
4. Optical Imaging Scheme of a Tattoo Dot Under Skin
According to one embodiment of the present invention, a tattoo dot serves as a SERS scattering agent. The tattoo dot may have a diameter in the range of approximately 0.1 to 5 mm. The diameter is advantageously approximately 1 mm. In practice, several tattoo dots may be implanted. Typically, only a single dot is probed at a time. However, the present invention also encompasses a method and system for probing multiple dots simultaneously to detect and quantify one or more analytes in vivo. FIG.5 illustrates an apparatus 40 according to one embodiment of the invention, in which Raman scattering from tattoo particles in the top layer of the dermis is measured. The apparatus 40 as shown in FIG.5 may, for example, be mounted in the housing 10 shown in either
The simulation results and the contour lines of absorbed energy in the z-r symmetrical plane for a published (Zuomin Zhao, “Pulsed Photoacoustic Techniques and Glucose Detection in Human Blood and Tissue” Ph.D. thesis, University Oulu, Finland 2002 p61) skin model are shown in FIG.6 for a narrow beam. The maximal absorption is located on a portion of the z-axis that is in the papillary dermis, not at the surface of the skin. This is mainly because the maximal absorption coefficient of the dermis is just under the epidermis. As shown in
In the simulation of
5. Optical Spectral Analysis
The following description presents two possible, exemplary embodiments of the present invention: of the, in one embodiment, an arm monitor head is separated from the laser and spectrograph and in an alternative embodiment, the arm monitor head is co-mounted with the laser and spectral monitor. FIG.8 shows a top view of an apparatus 80 accoridng to one embodiment of the invention with fiber couplings. In general, the skin is illuminated by radiation emitted from a launching fiber 82 which passes through a lens 84, bandpass filter 86, and beam splitter 90 before being reflected by the 45-degree mirror 92 to illuminate the skin. Raman radiation emitted by nano-particles embedded in the dermis of the skin is collected by a lens 94 oriented parallel to the skin (in the plane of the page), is reflected by the 45 degree mirror 92, and is then deflected by the beam splitter 90. The collected Raman radiation then passes through a notch filter 96 and a focusing lens 100 and is collected by a fiber bundle 102. The excitation laser is coupled into the monitor head via a single mode fiber 104. The Raman signal is coupled into a fiber bundle for feeding to a grating based spectrograph. The band pass filter 86 is used to improve the side mode suppression of the probe beam 106 which illuminates the tattoo particles (not shown). Raman generation within the launch fiber 82 and/or side mode emission from the laser can degrade the side mode suppression of the probe beam, and the bandpass filter 86 reduces the impact of these effects on instrument performance. The beam splitter 90 passes excitation laser light, advantageously having a wavelength of about 830 nm, while advantageously reflecting light with wavelengths longer than 866 nm. A super notch filter with a blocking power factor of approximately 106 (i.e., OD 6 at the laser wavelength) may be used to reduce elastically scattered laser radiation entering the fiber bundle. The Raman signal is frequency shifted in a range of approximately 600 to 1800 cm−1, which gives a wavelength range of approximately 873.5 nm to 975.8 nm. The Raman spectrum is advantageously collected using a grating based spectrograph (not shown). The fiber bundle may be used to collect photons for coupling into the spectrograph. Because SERS has a much stronger signal than regular Raman scattering, laser power for the incident excitation beam may be reduced to a lower level and detector requirements may be reduced to a level where lower efficiency, less expensive collectors, such as for example a silicon CCD, may provide sufficient performance. To reduce interference with the measurement from background fluorescence emissions caused by the excitation beam, the laser wavelength may be increased from approximately 830 nm to, for example approximately 980 nm or approximately 1064 nm. Higher wavelength incident radiation produces less fluorescence than lower wavelength (higher energy) light because fluorescence emissions generally scale with the inverse of the fourth power of the incident wavelength. For higher wavelength incident light, an InGaAs detector array may be used in place of the CCD. In a variation from the scheme illustrated in
Using SERS, a glucose Raman scattering signal may be selectively enhanced by more than a million times compared to other substances in the tissue. The glucose concentration is human tissue is approximately 100 mg dL−1 while the human tissue total mass is 100 g dL−1. This factor of one million enhancement may elevate the glucose signal to approximately one thousand times that of other tissues, assuming a similar Raman scattering cross section. In fact, the molecules in the SAM are also enhanced as shown in the spectra shown in
In an apparatus 120 according to a further embodiment of the present invention, illustrated in
For a laser at 830 nm, the two glucose bands at approximately 545 cm−1 and approximately 1064 cm−1 are at the wavelengths, approximately 869.3 nm and approximately 910.4 nm respectively. The SAM reference line for approximately 864 cm−1 is at approximately 894.1 nm. These three signals are selected by narrow band pass filters A, B, C as shown in
6. Spectral Lines in Comparison with Background
Glucose spectral lines may be interefered with by scattering from the single molecular layer of SAM on AgFON and possible tissue background. FIG.10 and FIG.11 illustrate glucose SERS analyses compared with AgFON itself, glucose, and skin Raman spectra. In
The spectral signals for two glucose bands (S(A) and S(C)) and one SAM band (S(B)) are first corrected by subtracting off the base line signal S(E) and then normalizing by the laser power S(D). The base line signal is an averaged signal of the spectrum excluding those three bands, which arises mainly from background signal and tissue fluorescence:
The Glucose signal is further normalized by the SAM signal, since the SERS glucose signal varies depending on how many silver particles are illuminated by the laser. Glucose signal variation could also come from the variation of how many particles are present in the tattoo spot and/or from the alignment of the laser spot onto the tattoo spot. However, these sources of variation of the glucose signal can all be removed by using the SAM signal (small particle background) as a reference.
The glucose concentration obtained from each line are then averaged with a weighting factor on each one. Because the spectral line intensity and back ground next to the line are different, likely errors of the two bands are different too. As a result, two weighting factors will be derived from spectral analysis and instrumental filter functions. The final glucose concentration signal, GC, is then obtained from:
Glucose concentration:
GC=g′GCI+g″GCII (7)
Where g′ and g″ are weighting factors and the sum of them is 1.
The foregoing description of specific embodiments and examples of the invention have been presented for the purpose of illustration and description, and although the invention has been illustrated by certain of the preceding examples, it is not to be construed as being limited thereby. They are not intended to be exhaustive or to limit the invention to the precise forms disclosed, and obviously many modifications, embodiments, and variations are possible in light of the above teaching. It is intended that the scope of the invention encompass the generic area as herein disclosed, and by the claims appended hereto and their equivalents.
This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/491,356, filed on Jul. 31, 2003, the disclosure of which is hereby incorporated by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
60491356 | Jul 2003 | US |